<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01550705</url>
  </required_header>
  <id_info>
    <org_study_id>UTINH</org_study_id>
    <secondary_id>U54DK083909</secondary_id>
    <nct_id>NCT01550705</nct_id>
  </id_info>
  <brief_title>Effect of Isoniazid on Protoporphyrin Levels in Erythropoietic Protoporphyria</brief_title>
  <acronym>INHEPP</acronym>
  <official_title>Quantification of the Effects of Isoniazid Treatment on Erythrocyte and Plasma Protoporphyrin IX Concentration and Plasma Aminolevulinic Acid in Patients With Erythropoietic Protoporphyria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In erythropoietic protoporphyria there is an accumulation of protoporphyrin IX (PPIX) in the&#xD;
      plasma and liver. The reason it builds up is either the last step to make heme, insertion of&#xD;
      iron into PPIX, is rate limiting or there is an increase in activity in the first step in the&#xD;
      heme pathway.&#xD;
&#xD;
      It may be possible to decrease the amount of PPIX made and see a decrease in symptoms. The&#xD;
      first step to make heme is the key step in the pathway and it uses vitamin B6 as a cofactor.&#xD;
      If the investigators can limit the amount of vitamin B6 the investigators can possibly reduce&#xD;
      the activity of this rate limiting step. With decreased activity of the enzyme it may be&#xD;
      possible for the body to utilize all the PPIX that is made so that none builds up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinically, both erythropoietic protoporphyria (EPP) and X-linked EPP (XLEPP) are&#xD;
      characterized by painful, non-blistering cutaneous photosensitivity with onset in early&#xD;
      childhood. EPP is the most common porphyria in children and the third most common in adults&#xD;
      (after porphyria cutanea tarda and acute intermittent porphyria). Reports of prevalence vary&#xD;
      between 5 and 15 cases per million population.&#xD;
&#xD;
      EPP is due in most cases to decreased activity of ferrochelatase (FECH), the enzyme that&#xD;
      catalyzes the incorporation of ferrous iron into PPIX, the final step in the production of&#xD;
      heme. The pattern of inheritance is autosomal recessive. However, homozygosity for a FECH&#xD;
      mutation is rare. Rather, the decreased activity is a consequence of a combination of an&#xD;
      inherited inactivating mutation affecting one FECH allele and an intronic polymorphism that&#xD;
      alters splicing of the other allele. The alternative splice site, when used, produces a&#xD;
      non-functional FECH messenger ribonucleic acid (mRNA). The alternative splice site is used&#xD;
      approximately 40% of the time. Therefore, the polymorphic allele produces approximately 60%&#xD;
      of normal FECH activity, and for this reason, is termed hypomorphic. When the hypomorphic&#xD;
      FECH allele is in trans with the non-functional mutant allele the result is 30% or less of&#xD;
      the normal FECH enzyme activity. This subnormal FECH activity becomes rate-limiting,&#xD;
      resulting in accumulation of intracellular PPIX. Although the defect is presumably expressed&#xD;
      in all tissues, the PPIX responsible for photosensitivity derives primarily from marrow&#xD;
      reticulocytes.&#xD;
&#xD;
      Aminolevulinic acid synthase (ALAS), the first, and rate-limiting enzyme in the heme&#xD;
      biosynthetic pathway, catalyzes the condensation of glycine and succinyl-Coenzyme A&#xD;
      (succinyl-CoA) to form aminolevulinic acid (ALA), and requires pyridoxal 5'-phosphate as a&#xD;
      cofactor. ALAS in mammalian cells is localized to the mitochondrial matrix. The enzyme is&#xD;
      synthesized as a precursor protein in the cytosol and transported into mitochondria. Two&#xD;
      separate ALA synthase genes encode housekeeping (tissue-nonspecific) and erythroid specific&#xD;
      forms of the enzyme (ALAS1 and ALAS2, respectively). The gene for human ALAS1 is on 3p.21 and&#xD;
      the locus for ALAS2 the X-chromosome, at Xp11.2.&#xD;
&#xD;
      The two forms of ALAS are differentially regulated, ALAS1 is a housekeeping gene expressed in&#xD;
      all cells and ALAS2 is driven by erythroid specific transcription factors GATA1 and NF-E2.&#xD;
      Additionally, ALAS2 mRNA contains an iron-responsive element (IRE) in its 5'-untranslated&#xD;
      region, similar to mRNAs encoding ferritin and the transferrin receptor (in which the IRE is&#xD;
      in the gene's 3' UTR). Gel retardation analysis showed that the iron-responsive element in&#xD;
      ALAS2 mRNA is functional [as evidenced by binding to iron regulator protein 2 (IRP2)],&#xD;
      indicating that translation of the erythroid-specific mRNA is directly linked to the&#xD;
      availability of iron and heme in erythroid cells. In this case, when intracellular iron&#xD;
      concentration is relatively high, it is available for binding to IRP2, a process that&#xD;
      enhances ubiquitin-mediated degradation of IRP2. Under these conditions, IRP2 is unavailable&#xD;
      for binding to the IRE element in ALAS2, clearing the message for efficient translation.&#xD;
      Conversely, when intracellular iron is relatively low, IRP2 degradation is restricted, making&#xD;
      the protein available for binding to the IRE and thereby blocking translation of ALAS2 mRNA.&#xD;
&#xD;
      Recently, a variant form of EPP, inherited in an X-linked pattern (XLEPP), was shown to be&#xD;
      due to an ALAS2 gain-of-function mutation in exon 11. The mutation results in a truncated&#xD;
      form of the protein that has supranormal specific activity as a result of less constrained&#xD;
      enzyme-substrate interactions, resulting in overproduction of PPIX. This situation is in&#xD;
      contrast to EPP with mutated FECH in which PPIX accumulates because of deficient heme&#xD;
      formation.&#xD;
&#xD;
      ALAS1 and 2 use pyridoxal phosphate (PLP) as a cofactor. PLP is a modified form of vitamin&#xD;
      B6. It has been shown that PLP complexes with isoniazid depleting the cofactor. This PLP&#xD;
      depletion has been one of the causes of sideroblastic anemia.&#xD;
&#xD;
      The investigators will test the hypothesis that depletion of PLP will lead to decreased&#xD;
      activity of ALAS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis demonstrated the treatment was not effective&#xD;
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Plasma Protoporphyrin IX Level</measure>
    <time_frame>Baseline and 3 Months</time_frame>
    <description>Plasma Protoporphyrin IX will be measured at baseline and at 3 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With Increased Sun Sensitivity</measure>
    <time_frame>Baseline and 3 Months</time_frame>
    <description>Study participants were asked to report after 3 months if they had experienced an increase in subjective measures of sun sensitivity during the trial. Reported outcome is the number of study participants who reported increased sun sensitivity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Erythropoietic Protoporphyria (EPP)</condition>
  <condition>X Linked Erythropoietic Protoporphyria</condition>
  <arm_group>
    <arm_group_label>Isoniazid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive isoniazid daily for 2 months. Subjects will be seen every 2 weeks to obtain lab samples and health check.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid</intervention_name>
    <description>Isoniazid 5 mg/Kg up to 300 mg per day. Oral tablets. 2 months.</description>
    <arm_group_label>Isoniazid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All subjects will be enrolled in the Longitudinal Study of the Porphyrias.&#xD;
&#xD;
          -  In patients with EPP the inclusion criteria are based on&#xD;
&#xD;
               1. clinical features&#xD;
&#xD;
               2. biochemical findings, as documented by laboratory reports of porphyria-specific&#xD;
                  testing performed after 1980&#xD;
&#xD;
               3. molecular findings documenting the identification of a mutation in FECH or ALAS2&#xD;
                  genes (molecular evidence of EPP is required for inclusion in the study).&#xD;
&#xD;
        These data will be obtained from the Porphyria Rare Disease Clinical Research Consortium&#xD;
        Longitudinal Study (RDCRN Protocol 7201). An individual must be willing to give written&#xD;
        informed consent and be 18 years of age or greater.&#xD;
&#xD;
        Autosomal EPP (EPP) and X-linked protoporphyria (XLEPP)&#xD;
&#xD;
        Clinical features - a or b required&#xD;
&#xD;
          -  A history of non-blistering cutaneous photosensitivity, usually with early age of&#xD;
             onset.&#xD;
&#xD;
          -  A diagnosis of EPP or XLEPP in a relative.&#xD;
&#xD;
        Biochemical findings&#xD;
&#xD;
          -  A marked increase in erythrocyte protoporphyrin [total erythrocyte protoporphyrin &gt;200&#xD;
             ug/dL, or more than 1.5-fold increase relative to upper limit of normal of 80 ug/dL,&#xD;
             with a predominance of free protoporphyrin (85-100% in EPP and 50-85% in XLEPP). Note:&#xD;
             Methods in some laboratories for measuring free erythrocyte protoporphyrin (FEP)&#xD;
             actually measure zinc protoporphyrin, so these results cannot be relied upon for&#xD;
             diagnosis or characterizing the phenotype in EPP and XLEPP.&#xD;
&#xD;
          -  Increased plasma porphyrins with a fluorescence emission peak at ~634 nm.&#xD;
&#xD;
          -  Normal urinary porphyrins (except in patients with hepatobiliary impairment), and&#xD;
             normal ALA and porphobilinogen (PBG).&#xD;
&#xD;
        Molecular findings - one of the following:&#xD;
&#xD;
          -  A disease causing FECH mutation trans to the IVS3-48C&gt;T low expression FECH allele&#xD;
             (aEPP)&#xD;
&#xD;
          -  Two disease-causing FECH mutations (EPP, recessive variant)&#xD;
&#xD;
          -  A gain-of-function ALAS2 C-terminal deletion/exon 11 mutation (XLEPP)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of EPP that cannot be documented by DNA testing.&#xD;
&#xD;
          -  Patients with evidence of active liver injury as defined by serum transaminase&#xD;
             concentrations greater than three times the upper limit of normal, those with a&#xD;
             history of recent (within 3 months of enrollment) or ongoing alcohol abuse, those with&#xD;
             diabetes mellitus requiring therapy, renal insufficiency (serum creatinine &gt;2.0 mg/ml)&#xD;
             or evidence of malnutrition (based on subnormal plasma concentration of transthyretin)&#xD;
             will be ineligible for participation in the study.&#xD;
&#xD;
          -  Pregnant and/or lactating women will be excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John D Phillips, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah School of Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.porphyriafoundation.com/</url>
    <description>American Porphyria Foundation</description>
  </link>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>March 5, 2012</study_first_submitted>
  <study_first_submitted_qc>March 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2012</study_first_posted>
  <results_first_submitted>November 19, 2016</results_first_submitted>
  <results_first_submitted_qc>November 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 16, 2017</results_first_posted>
  <last_update_submitted>November 19, 2016</last_update_submitted>
  <last_update_submitted_qc>November 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>John Phillips</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Protoporphyria</keyword>
  <keyword>Porphyria</keyword>
  <keyword>Porphyrins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Protoporphyria, Erythropoietic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Isoniazid</title>
          <description>Subjects will receive isoniazid daily for 2 months. Subjects will be seen every 2 weeks to obtain lab samples and health check.&#xD;
Isoniazid: Isoniazid 5 mg/Kg up to 300 mg per day. Oral tablets. 2 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Isoniazid</title>
          <description>Subjects will receive isoniazid daily for 2 months. Subjects will be seen every 2 weeks to obtain lab samples and health check.&#xD;
Isoniazid: Isoniazid 5 mg/Kg up to 300 mg per day. Oral tablets. 2 months.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Protoporphyria Type</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Erythropoietic Protoporphyria (EPP)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>X-linked Erythropoietic Protoporphyria (XLEPP)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Protoporphyrin IX level</title>
          <units>micrograms per deciliter (µg/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.3" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Plasma Protoporphyrin IX Level</title>
        <description>Plasma Protoporphyrin IX will be measured at baseline and at 3 months</description>
        <time_frame>Baseline and 3 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Isoniazid</title>
            <description>Subjects will receive isoniazid daily for 2 months. Subjects will be seen every 2 weeks to obtain lab samples and health check.&#xD;
Isoniazid: Isoniazid 5 mg/Kg up to 300 mg per day. Oral tablets. 2 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Plasma Protoporphyrin IX Level</title>
          <description>Plasma Protoporphyrin IX will be measured at baseline and at 3 months</description>
          <units>µg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Increased Sun Sensitivity</title>
        <description>Study participants were asked to report after 3 months if they had experienced an increase in subjective measures of sun sensitivity during the trial. Reported outcome is the number of study participants who reported increased sun sensitivity</description>
        <time_frame>Baseline and 3 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Isoniazid</title>
            <description>Subjects will receive isoniazid daily for 2 months. Subjects will be seen every 2 weeks to obtain lab samples and health check.&#xD;
Isoniazid: Isoniazid 5 mg/Kg up to 300 mg per day. Oral tablets. 2 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Increased Sun Sensitivity</title>
          <description>Study participants were asked to report after 3 months if they had experienced an increase in subjective measures of sun sensitivity during the trial. Reported outcome is the number of study participants who reported increased sun sensitivity</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Isoniazid</title>
          <description>Subjects will receive isoniazid daily for 2 months. Subjects will be seen every 2 weeks to obtain lab samples and health check.&#xD;
Isoniazid: Isoniazid 5 mg/Kg up to 300 mg per day. Oral tablets. 2 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v4.03</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like Symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE v4.03</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Productive Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John D. Phillips, Ph.D.</name_or_title>
      <organization>University of Utah</organization>
      <phone>801-581-6650</phone>
      <email>john.phillips@hsc.utah.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

